BIO vs. RVTY: Bio-Rad Laboratories vs. Revvity Stock Comparison
How do Bio-Rad Laboratories (BIO) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and Revvity (RVTY) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | BIO | RVTY |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | Revvity Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.26 billion USD | 17.31 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | February 27, 1980 | February 21, 1973 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | RVTY |
|---|---|---|
| Total Return (1Y) | 28.31% | 76.75% |
| Total Return (3Y, Annualized) | 8.52% | 24.22% |
| Total Return (5Y, Annualized) | -11.74% | -1.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | RVTY |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 40.22% |
| Beta (5Y) | 1.03 | 1.07 |
| Max Drawdown (5Y) | -72.24% | -59.01% |
| Avg. Volume (3M) | 250.78K | 1.89M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | RVTY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | 1.80 |
| Sortino Ratio (1Y) | 0.98 | 2.90 |
Profitability
ROE (TTM)
Bio-Rad Laboratories (BIO) at 14.27% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for BIO.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.45%
- Max
- 109.18%
- Q3
- 6.23%
- RVTY
- 3.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.61%
- Max
- 18.05%
- RVTY
- 8.61%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Revvity (RVTY) at 17.06% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.06%
- Max
- 83.12%
- RVTY
- 17.06%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | RVTY |
|---|---|---|
| ROE (TTM) | 14.27% | 3.45% |
| ROA (TTM) | 1.50% | 2.54% |
| Net Margin (TTM) | 39.45% | 8.61% |
| Operating Margin (TTM) | 11.82% | 17.06% |
| Gross Margin (TTM) | 52.19% | 55.91% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO) at 0.65% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Revvity (RVTY) reports EPS growth of -5.91%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.
Growth Metrics
| Metric | BIO | RVTY |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 3.67% |
| Revenue Growth (3Y CAGR) | -2.68% | -4.82% |
| EPS Growth (YoY) | -- | -5.91% |
| EPS Growth (3Y CAGR) | -- | -23.26% |
Financial Strength
Current Ratio (MRQ)
Both Bio-Rad Laboratories (BIO) at 3.18 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.65
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- RVTY
- 2.65
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Bio-Rad Laboratories (BIO) at 0.18 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- RVTY
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | RVTY |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 2.65 |
| Debt / Equity (MRQ) | 0.18 | 0.38 |
| Net Debt / EBITDA | -0.73 | 2.43 |
Dividends
Dividend Yield (TTM)
Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19%
- RVTY
- 0.19%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.40%
- RVTY
- 13.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | RVTY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.19% |
| Dividend Payout Ratio (TTM) | 0.00% | 13.40% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Revvity (RVTY) at 68.94 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
68.94
- Max
- 85.34
- RVTY
- 68.94
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.88
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- RVTY
- 5.88
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Revvity (RVTY) at 2.39 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.39
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- RVTY
- 2.39
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO | RVTY |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | 68.94 |
| P/S Ratio (TTM) | 3.96 | 5.88 |
| P/B Ratio (MRQ) | 1.35 | 2.39 |
| Free Cash Flow Yield (TTM) | 2.65% | 3.62% |